Volume 10, Number 11—November 2004
Research
Histopathologic Improvement with Lymphedema Management, Léogâne, Haiti
Susan F. Wilson*, Jeannette Guarner*, Alix L. Valme†, Jacky Louis-Charles†, Tara L. Jones*, and David G. Addiss*
Table 4
Demographic, physical, and treatment-related characteristics of 27 patients with initial and follow-up skin biopsy specimens, by degree of histologic improvement (involving >4 vs. <4 histologic characteristics), Léogâne, Haiti
| Factors examined | Improvement in >4 histologic characteristics | Improvement in <4 histologic characteristics |
|---|---|---|
| Number of patients | 11 | 16 |
| Female (%) | 9 (82) | 11 (69) |
| Median age, y (range) | 39 (20–61) | 32 (16–61) |
| Stage of lymphedema (%) | ||
| Stage 1 | 2 (18) | 0 (0) |
| Stage 2 | 5 (45) | 13 (81) |
| Stage 3 | 4 (36) | 3 (19) |
| Median no. of days in lymphedema management before 1st biopsy (range) | 21 (0–432) | 19.5 (0–468) |
| Median no. of days between biopsies (range) | 359 (317–503) | 366 (317–656) |
| Median annual incidence of ADLA between biopsies (range) | 0 (0–2) | 0 (0–3) |
| Median duration of lymphedema, y (range) | 11.5 (4–27) | 7 (0–25) |
Page created: April 22, 2011
Page updated: April 22, 2011
Page reviewed: April 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.